Compare Stocks → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CMMBNYSE:IKTNASDAQ:PMNNASDAQ:VIRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$0.73-18.1%$0.75$0.42▼$1.89$8.01M0.39196,500 shs423,449 shsIKTInhibikase Therapeutics$1.40+11.1%$2.03$0.79▼$4.35$9.07M1.31118,995 shs34,551 shsPMNProMIS Neurosciences$1.92+1.1%$2.03$0.95▼$8.95$36.49M0.6735,098 shs1,617 shsVIRXViracta Therapeutics$0.82$0.95$0.43▼$2.38$32.24M0.95102,561 shs26,818 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics-18.42%-0.06%-8.30%+20.83%-54.11%IKTInhibikase Therapeutics+11.11%+3.70%-36.65%-49.09%-61.86%PMNProMIS Neurosciences+1.24%+0.30%-19.81%-2.80%-68.86%VIRXViracta Therapeutics+0.12%+0.11%-23.27%+46.58%-23.27%How Biden has already won 2024 (Ad)Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.Click here to watch this now before it’s too late. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMMBChemomab Therapeutics3.0544 of 5 stars3.55.00.00.02.51.70.6IKTInhibikase Therapeutics1.4668 of 5 stars3.50.00.00.00.01.71.3PMNProMIS Neurosciences2.1094 of 5 stars3.54.00.00.00.61.70.6VIRXViracta Therapeutics0.9768 of 5 stars3.52.00.00.00.00.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMMBChemomab Therapeutics3.00Buy$6.50796.55% UpsideIKTInhibikase Therapeutics3.00Buy$27.001,828.57% UpsidePMNProMIS Neurosciences3.00Buy$8.00315.67% UpsideVIRXViracta Therapeutics3.00Buy$7.00752.62% UpsideCurrent Analyst RatingsLatest VIRX, IKT, CMMB, and PMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2024CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$6.004/17/2024VIRXViracta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$13.004/16/2024VIRXViracta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/5/2024IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00(Data available from 5/9/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/AIKTInhibikase Therapeutics$260K34.89N/AN/A$1.78 per share0.79PMNProMIS Neurosciences$10K3,649.23N/AN/A$0.20 per share9.62VIRXViracta TherapeuticsN/AN/AN/AN/A$0.33 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMMBChemomab Therapeutics-$24.22M-$2.12N/AN/AN/AN/A-114.00%-88.53%5/9/2024 (Confirmed)IKTInhibikase Therapeutics-$19.03M-$3.56N/AN/AN/A-5,886.15%-107.54%-91.82%5/20/2024 (Estimated)PMNProMIS Neurosciences-$13.21M-$1.13N/AN/AN/AN/AN/A-141.23%5/20/2024 (Estimated)VIRXViracta Therapeutics-$51.06M-$1.32N/AN/AN/AN/A-172.32%-71.40%5/13/2024 (Estimated)Latest VIRX, IKT, CMMB, and PMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/ACMMBChemomab Therapeutics-$0.20N/A+$0.20N/AN/AN/A4/1/2024Q4 2023PMNProMIS NeurosciencesN/A-$0.09-$0.09-$0.09N/AN/A3/27/2024Q4 2023IKTInhibikase Therapeutics-$0.78-$0.63+$0.15-$0.63N/AN/A 3/7/202412/31/2023CMMBChemomab Therapeutics-$0.40-$0.26+$0.14-$0.26N/AN/A 3/7/2024Q4 2023VIRXViracta Therapeutics-$0.30-$0.35-$0.05-$0.35N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMMBChemomab TherapeuticsN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/AVIRXViracta TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMMBChemomab TherapeuticsN/A4.324.32IKTInhibikase TherapeuticsN/A4.134.13PMNProMIS NeurosciencesN/A1.461.46VIRXViracta TherapeuticsN/A1.431.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMMBChemomab Therapeutics46.05%IKTInhibikase Therapeutics3.81%PMNProMIS Neurosciences50.13%VIRXViracta Therapeutics31.37%Insider OwnershipCompanyInsider OwnershipCMMBChemomab Therapeutics11.91%IKTInhibikase Therapeutics20.30%PMNProMIS Neurosciences10.30%VIRXViracta Therapeutics7.42%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCMMBChemomab Therapeutics2011.05 million9.73 millionNot OptionableIKTInhibikase Therapeutics86.48 million5.16 millionNot OptionablePMNProMIS Neurosciences618.96 million17.01 millionNot OptionableVIRXViracta Therapeutics4039.27 million36.36 millionOptionableVIRX, IKT, CMMB, and PMN HeadlinesSourceHeadlineViracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conferenceglobenewswire.com - May 7 at 4:05 PMDay One wins FDA nod for brain cancer therapy, Ojemdamsn.com - April 23 at 3:26 PMPromising Clinical Trial Results Reinforce Buy Rating for Viracta Therapeuticsmarkets.businessinsider.com - April 18 at 7:46 AMAnalysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)markets.businessinsider.com - April 17 at 12:57 PMAnalysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)markets.businessinsider.com - April 16 at 3:51 PMViracta Eyes FDA Accelerated Approval Path for Nana-val in EBV-Positive PTCLprecisionmedicineonline.com - April 16 at 10:50 AMWhy Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?msn.com - April 15 at 1:27 PMViracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphomaglobenewswire.com - April 15 at 8:00 AMViracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwanglobenewswire.com - April 1 at 8:30 AMViracta Therapeutics CFO and COO Dan Chevallard resignsinvesting.com - March 22 at 9:44 PMBuy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid Financialsmarkets.businessinsider.com - March 12 at 2:39 PMVIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023msn.com - March 8 at 9:38 AMViracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 7 at 4:05 PMViracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trialglobenewswire.com - February 29 at 8:00 AMVIRX Mar 2024 2.500 callfinance.yahoo.com - February 17 at 9:42 AMViracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 6 at 8:23 PMViracta Therapeutics Provides Clinical Update and Outlook for 2024finance.yahoo.com - January 4 at 10:14 AMTaking a Closer Look At Viracta Therapeutics Inc (VIRX) Following Its Recent Tradeknoxdaily.com - January 1 at 8:28 AMViracta Therapeutics Stock (NASDAQ:VIRX) Dividends: History, Yield and Datesbenzinga.com - December 22 at 7:49 PMViracta gets orphan drug status for Nana-val for EBV tumorsmsn.com - December 12 at 3:20 PMViracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinomafinance.yahoo.com - December 12 at 10:19 AMViracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levelsfinance.yahoo.com - December 4 at 9:39 AMViracta Therapeutics Inc VIRXmorningstar.com - November 18 at 2:25 PMA company insider recently sold 3,512 shares of Viracta Therapeutics Inc [VIRX]. Should You Sale?knoxdaily.com - November 9 at 11:39 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsChemomab TherapeuticsNASDAQ:CMMBChemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Inhibikase TherapeuticsNYSE:IKTInhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.ProMIS NeurosciencesNASDAQ:PMNProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Viracta TherapeuticsNASDAQ:VIRXViracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.